COMMUNIQUÉS West-GlobeNewswire

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
19/03/2026
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, [...]
Evermore Expands Community Health Access in Ohio Through New Partnership with Discount Drug Mart
19/03/2026
BENTONVILLE, Ark., March 19, 2026 (GLOBE NEWSWIRE) -- evermore, the personalized health benefits platform transforming how people access the resources they need to live healthier lives, today announced a new retail [...]
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
19/03/2026
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading [...]
Passing of Genmab A/S’ Annual General Meeting
19/03/2026
Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management and the year’s [...]
Causeway Therapeutics Presents Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis at RNA Leaders Europe 2026
19/03/2026
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced [...]
Notice to convene Evaxion’s Annual General Meeting
19/03/2026
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General [...]
Diadia Launches AI Platform to Finally Give Women Answers to "Unexplained" Health Problems
19/03/2026
Former Google and Reddit AI scientist builds tool to decode genetic clues standard medicine dismisses as "normal" NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- For women suffering from unexplained infertility, crushing [...]
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
19/03/2026
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
19/03/2026
Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta STOCKHOLM, [...]
Les résultats 2025 de Roquette illustrent la résilience d’un portefeuille élargi, dans un contexte de marché très exigeant
19/03/2026
Les résultats 2025 de Roquette illustrent la résilience d’un portefeuille élargi, dans un contexte de marché très exigeant La stratégie du Groupe et ses acquisitions récentes lui permettent de monter en gamme sur des [...]
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
19/03/2026
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term [...]
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment
19/03/2026
Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment The Group’s strategy and recent acquisitions enable upselling to higher-value markets +8% turnover growth to € [...]
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
19/03/2026
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage [...]
Dr. Myung Ju Lee of VIP Plastic Surgery Receives Minister of Health and Welfare Award at Medical Korea 2026
19/03/2026
National honor recognizes Dr. Lee’s leadership in advancing Korea’s global healthcare standards and excellence in facial plastic surgery SEOUL, Korea, March 19, 2026 (GLOBE NEWSWIRE) -- Myung Ju Lee, MD, PhD, founder of [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
19/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
18/03/2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
18/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18/03/2026
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and [...]
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
18/03/2026
Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 [...]

Pages